Targeting transcription factors for cancer prevention - The case of Nrf2

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 153-155

  Colburn, Nancy H ^a   Kensler, Thomas W ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2;

ANIMAL; DIET THERAPY; DISEASE COURSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETICS; MOUSE; MOUSE MUTANT; NEOPLASM; NOTE; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, KNOCKOUT; NEOPLASMS; NF-E2-RELATED FACTOR 2; TRANSCRIPTION FACTORS;

EID: 61749088271     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0025     Document Type: Review

References (18)

1. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
2. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
3. Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006;28:813-8.
4. Khor T, Huang M-T, Prawan A. Increased susceptibility of Nrf-2-knock-out mice to colitis-associated colorectal cancer. Cancer Prev Res 2008. In press.
5. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
6. Bharti AC, Aggarwal BB. Nuclear factor-?B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
7. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8.
8. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118: 285-96.
9. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006; 12:3661-97.
10. Xu C, Huang MT, Shen G, et al. Inhibition of 7,12- dimethylbenz(a) anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 2006;66:8293-6.
11. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 1999;96:9827-32.
12. Matthews CP, Birkholz AM, Baker AR, et al. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res 2007;67:2430-8.
13. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-κ B and Pdcd4. Trends Mol Med 2003;9:36-41.
14. Shen Q, Uray IP, Li Y, et al. Targeting the AP-1 transcription factor for the prevention of estrogen receptor (ER)-negative mammary tumors. Cancer Prev Res 2008. In press.
15. Korashy H, El-Kadi A. The role of redox-sensitive transcription factors NF-κ B and AP-1 in the modulation of the Cyp1a1 gene by mercury, lead, and copper. Free Radic Biol Med 2008; 44:795-806.
16. Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001;98:3410-5.
17. Healy ZR, Lee NH, Gao X, et al. Divergent responses of chondrocytes and endothelial cells to shear stress: cross-talk among COX-2, the phase 2 response, and apoptosis. Proc Natl Acad Sci U S A 2005;102:14010-5.
18. Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.